Patents by Inventor Barbara A. Osborne

Barbara A. Osborne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110067122
    Abstract: The present invention relates to the production of a transgenic ungulate which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.
    Type: Application
    Filed: February 9, 2009
    Publication date: March 17, 2011
    Applicant: Kyowa Hakko Kirin Co., Ltd.
    Inventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne
  • Patent number: 7820878
    Abstract: The present invention relates to a method of producing an ungulate having both copies of the IgM heavy chain (mu) rag-1 and/or rag-2 gene eliminated from its genome. Animals which have IgM, rag-1 and/or rag-2 eliminated from their genome are unable to conduct the gene rearrangements that are necessary to generate the antigen receptors of B- or T-lymphocytes, and therefore will not develop native B- or T-cells. Because they are unable to produce B- and T-lymphocytes, these IgM, rag-1, or rag-2 ungulates cannot reject human hematopoietic stem cell preparations, and B- and T-lymphocytes which develop therefrom. Therefore, the present invention also involves injecting into IgM, rag-1, and/or rag-2 deficient ungulates, in utero or shortly after birth, human B- and T-lymphocytes whose immune systems produce human immunoglobulin that can be processed for therapeutic uses in humans.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: October 26, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Richard A. Goldsby, James M. Robl, Barbara A. Osborne, Yoshimi Kuroiwa
  • Publication number: 20090276866
    Abstract: The present invention relates to a method of producing an ungulate having both copies of the IgM heavy chain (mu) rag-1 and/or rag-2 gene eliminated from its genome. Animals which have IgM, rag-1 and/or rag-2 eliminated from their genome are unable to conduct the gene rearrangements that are necessary to generate the antigen receptors of B- or T-lymphocytes, and therefore will not develop native B- or T-cells. Because they are unable to produce B- and T-lymphocytes, these IgM, rag-1, or rag-2 ungulates cannot reject human hematopoietic stem cell preparations, and B- and T-lymphocytes which develop therefrom. Therefore, the present invention also involves injecting into IgM, rag-1, and/or rag-2 deficient ungulates, in utero or shortly after birth, human B- and T-lymphocytes whose immune systems produce human immunoglobulin that can be processed for therapeutic uses in humans.
    Type: Application
    Filed: May 5, 2008
    Publication date: November 5, 2009
    Inventors: Richard A. Goldsby, James M. Robl, Barbara A. Osborne, Yoshimi Kuroiwa
  • Patent number: 7491867
    Abstract: The present invention relates to the production of a transgenic bovine which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: February 17, 2009
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne
  • Patent number: 7074983
    Abstract: The present invention relates to the production of a transgenic bovine which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: July 11, 2006
    Assignees: Kirin Beer Kabushiki Kaisha, Hematech, LLC
    Inventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne